A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
To investigate whether 24 months of idebenone may reduce the progression from Prodromal
Parkinson disease (PPD) to Parkinson disease (PD).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Beijing Hospital Beijing Tiantan Hospital Guizhou Medical University Huashan Hospital Jiangsu Province Nanjing Brain Hospital Peking Union Medical College Hospital Peking University Shenzhen Hospital Qilu Hospital of Shandong University Second Affiliated Hospital of Soochow University Sir Run Run Shaw Hospital The Affiliated Hospital of Hangzhou Normal University The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Dalian Medical University The First Affiliated Hospital of Guangzhou Medical University Tongji Hospital West China Hospital Wuhan Union Hospital, China Xinhua Hospital, Shanghai Jiao Tong University School of Medicine